HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis assumes AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of $95.
HC Wainwright & Co. analyst Joseph Pantginis assumes AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of $95.